Sunactic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sunactic

What is Sunactic? Defining the Medicine's Identity

Property Description
Active Ingredient Diclofenac Sodium
Form Topical Gel
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Management of localized inflammation and pain
Origin Synthetic compound

Sunactic is a pharmaceutical product containing the core active ingredient Diclofenac Sodium, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This substance is a synthetic compound derived from phenylacetic acid. Its primary pharmacological role is to manage the symptoms of pain and inflammation, with its specific formulation as a topical gel representing a distinct route of administration.

Sunactic: Defining Its Pharmacological Class and Origin

Sunactic belongs to the NSAID class, functioning primarily as a potent cyclooxygenase (COX) inhibitor and a recognized anti-rheumatic agent. This core mechanism, which involves interfering with the synthesis of prostaglandins, is noted for providing relief across various inflammatory disorders. The formulation as a gel, rather than an oral tablet, emphasizes its positioning for use where localized application is preferred, minimizing systemic exposure.

Active Ingredient and Available Pharmaceutical Forms

The active ingredient in Sunactic is Diclofenac Sodium, typically delivered in a topical gel form. Unlike many oral Diclofenac products that contain different salt forms, Sunactic's focus is the cutaneous route of administration via a gel preparation. This topical format is designed to deliver the Diclofenac directly through the skin, enabling targeted action for localized symptoms of pain and swelling. The product is manufactured and distributed under its specific trade name.

The General Therapeutic Purpose of Sunactic

The primary purpose of Sunactic is to address common physical symptoms through its tripartite action: providing an analgesic effect, exerting an anti-inflammatory effect, and offering antipyretic action. These combined functions mean the medicine is generally utilized to reduce swelling and alleviate localized pain, such as discomfort associated with sprains or joint conditions. The compound functions by inhibiting the biological signals of inflammation, making it a choice for symptomatic management.

What side effects are possible with Sunactic?

Possible Side Effects and Safety Information

The safety profile of Sunactic (Diclofenac Sodium Topical Gel) is officially categorized by both local application site reactions and the potential for systemic adverse events associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) class.


Adverse Reaction Classifications

Adverse reactions are formally classified by frequency and System-Organ-Class (SOC) in regulatory documents.

Classification Aspect Examples Official Frequency
Application Site Dermatitis, pruritus (itching), erythema, rash, burning sensation. Common (1–10%)
Systemic/Postmarketing Serious skin reactions (SJS, TEN), anaphylactic reactions, vision changes. Frequency Not Known

Serious Adverse Reactions

The official labeling for NSAIDs, including Diclofenac, highlights the risk of serious, potentially fatal, systemic events. These include Serious Cardiovascular Thrombotic Events such as myocardial infarction (heart attack) and stroke. The risk of Serious Gastrointestinal Adverse Events, including bleeding, ulceration, and perforation of the stomach or intestines, is also documented. These systemic risks may occur early and are noted to increase with the duration of use.


Population-Specific Safety Constraints

The medicine is contraindicated for use in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery and after about 30 weeks of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. Older adults are officially considered to be at greater risk for serious gastrointestinal and renal adverse events.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Sunactic (Diclofenac Sodium) overdose addresses the systemic effects that can result from excessive absorption or accidental ingestion.

Overdose Scope: Documented Manifestations

Overdose presentations, as detailed in regulatory documents, include gastrointestinal effects such as nausea, vomiting (potentially bloody or resembling coffee grounds), diarrhea, and stomach pain. Neurological signs like dizziness, confusion, drowsiness, and headache are also documented. Severe outcomes involve seizures, coma, and toxicity to key physiological systems: Gastrointestinal (bleeding, perforation), Cardiovascular (myocardial infarction, stroke, blood pressure changes), and Renal (acute kidney failure, little or no urine output).

Emergency Actions and Management

Immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted immediately if symptoms involve chest pain, difficulty breathing, weakness on one side of the body, or signs of severe internal bleeding (bloody vomit, black/tarry stools).

Management is symptomatic and supportive, as no specific antidote is known. Procedures may include the administration of activated charcoal if ingestion was recent and substantial. Hospital monitoring of vital signs, including ECG and blood/urine tests, is required to manage potentially life-threatening complications. Overdose risk is considered higher in the elderly and those with existing renal or hepatic impairment.

Therapeutic Uses of Sunactic

What Sunactic Treats: Main Uses and Benefits

Sunactic (Diclofenac Sodium Topical Gel) is commonly used to provide targeted symptomatic support for physical discomfort and swelling in specific, localized areas. It is relevant in therapeutic contexts where additional symptomatic management is appropriate.

This medication is commonly used across domains where additional symptomatic support is needed, and is relevant in conditions characterized by periods of heightened symptoms, in situations where patients experience localized discomfort from osteoarthritis (OA), and for addressing acute localized injuries like sprains and strains.

“It is applied in contexts involving inflammatory or irritative states and is relevant for managing symptoms that create noticeable physiological strain.”

Provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Is relevant for easing symptoms related to inflammatory or irritative states and physical discomfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sunactic? (Regulatory Eligibility Profile)

The eligibility for using Sunactic (Diclofenac Sodium Topical Gel) is strictly defined by regulatory authorities based on a patient’s medical history, age, and physiological status. This information is derived exclusively from government-approved labeling.


Contraindicated Populations and Conditions

Sunactic must not be used by patients who fall into the following categories:

  • Patients with a known hypersensitivity to diclofenac or any other component of the product.
  • Individuals with a history of asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs.
  • Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Women who are in their third trimester of pregnancy (starting at about 30 weeks gestation).
  • Children and adolescents under 14 years of age, as safety and efficacy are not established in this population.

Populations Requiring Conditional Use

Use requires caution or is generally advised to be avoided in:

  • Patients with advanced renal disease or severe heart failure.
  • Elderly patients (ge 65 years) due to increased risk of serious adverse events.
  • Females who are attempting to conceive or are in the first and second trimesters of pregnancy.

What should I know about interactions with other medicines?

The interaction profile for Sunactic (Diclofenac Sodium Topical Gel) is defined by pharmacokinetic and pharmacodynamic relationships, primarily referencing interactions known to occur with the systemic NSAID class.

Contraindicated Combinations

The product is contraindicated for use in the perioperative period of Coronary Artery Bypass Graft (CABG) surgery. It is also contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Documented Drug Interactions

Classification Interacting Substances/Classes Interaction Mechanism/Outcome
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin), Aspirin, SSRIs/SNRIs Increased risk of serious gastrointestinal bleeding.
Pharmacodynamic Attenuation Diuretics (e.g., Furosemide), ACE Inhibitors/ARBs Diminished antihypertensive or natriuretic effect.
Pharmacokinetic Alteration Voriconazole (strong CYP inhibitor), Digoxin, Lithium Voriconazole increases diclofenac exposure; may increase serum concentrations of Digoxin and Lithium.

Co-administration with other topical products on the same application site has not been studied and must be avoided as a general restriction. The combination with alcohol is also associated with an increased risk of serious gastrointestinal bleeding. In high-risk populations, specifically the elderly, volume-depleted, or those with renal impairment, the interaction with ACE Inhibitors/ARBs may result in a greater risk of renal function deterioration.

Mechanism of Action

Modulation of Inflammatory Mediator Synthesis

Sunactic's mechanism involves the competitive inhibition of cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This enzymatic blockade interrupts the arachidonic acid cascade, reducing the synthesis of pro-inflammatory mediators, primarily prostaglandins (PGE2). This action directly modulates the biochemical components of the inflammatory cascade.

Reduction of Peripheral Nociceptive Sensitization

By suppressing the production of prostaglandins at the injury site, the mechanism reduces the sensitization of peripheral afferent nerve endings. Prostaglandins are key substances that lower the excitability threshold of these nerves. The resulting reduction in nerve sensitization influences nociceptive signal transmission.

Influence on Local Vascular Dynamics

The mechanism also influences local vascular dynamics. Reduced prostaglandin levels support the modulation of excessive local vasodilation and increased vascular permeability. This physiological adjustment influences the factors that regulate fluid influx and vascular permeability, influencing local tissue microcirculation dynamics. The molecular action does not influence the foundational pathological mechanisms, and its activity is dependent on achieving adequate local tissue concentrations.

Dosage and Administration Information

How to Use Sunactic (Diclofenac Sodium Topical Gel 1%)

Sunactic is administered via the cutaneous route, meaning the gel is applied topically to the skin. The usage protocol involves adherence to specific dosage, frequency, and application technique.

Standard Dosing and Frequency

The standard regimen involves applying the gel four times daily (QID) to the specific joint area requiring support. The amount of gel to be applied depends on the joint location:

Joint Location Dose per Application Maximum Daily Total Dose
Upper Extremities (e.g., hand, elbow) 2 grams Up to 32 g across all joints
Lower Extremities (e.g., knee, foot) 4 grams Up to 32 g across all joints

For accurate delivery, the dose must be measured using the specific dosing card supplied with the product. The medicine is generally intended for the shortest duration necessary for relief, with use for localized issues often reviewed after seven days.


Application Procedures and Use Conditions

Proper use involves gently massaging the measured amount of gel into the entire affected joint. Following application, the user must wash their hands immediately, unless the hands are the area being treated. The application instructions specify not washing the treated area for at least one hour after application.

Usage restrictions state that the gel must only be applied to intact, non-diseased skin and must not be covered with occlusive (airtight) dressings or subjected to external heat. While the usual adult dosage may be used in older adults, the formulation is noted for exclusion in patients with advanced renal disease due to the potential for systemic exposure.

Recent Clinical Evidence

Sunactic: Recent Clinical Evidence

This section summarizes research evidence and provides an overview of clinical studies exploring the compound Sunactic (diclofenac sodium 3% gel) in its approved indication for Actinic Keratosis (AK).


Overview of Clinical Research

Clinical trials have investigated administration of the drug to participants with moderate to severe symptoms of AK. These studies focused on assessing changes in lesion counts following treatment. Research has indicated that a small percentage of individuals may experience skin reactions upon initial administration.

  • Phase 3 Trial Findings (Long-term) In a Phase 3 study, a sustained reduction in disease activity was observed over 52 weeks in the treatment group. The study reported a reduction in target lesion number scores and an improvement in cumulative lesion clearance. For example, in one trial, 50% of patients demonstrated complete clearance of target lesions 30 days following a 90-day treatment course.

  • Pooled Analysis and Specialized Populations A pooled analysis of RCTs evaluated the drug in combination with standard-of-care. Comparative studies have also investigated Sunactic's use alongside other common AK treatments, such as 5-fluorouracil and imiquimod, to assess non-inferiority or other potential differences in outcomes.


Efficacy and Safety Data Summary

Trial Outcome Metric Timeframe Studied Observation
75% Clearance (Target Lesions) 1 Year Post-Treatment Up to 91% of participants achieved this level of clearance in one long-term study.
100% Clearance (Cumulative Lesions) 1 Year Post-Treatment 30% of participants achieved complete clearance in the same long-term study.

Safety data were collected from adults participating in the trials. The most common adverse events included local skin irritation, headache, fatigue, and nausea. Data indicated participants did not withdraw due to adverse events at an unusual rate, suggesting a generally manageable safety profile in the clinical trial environment.

  • Potential Further Applications Preliminary research has explored the drug’s effects for related skin conditions such as Actinic Cheilitis and Disseminated Superficial Actinic Porokeratosis. These investigations are currently in early stages and do not constitute approval or recommendation for use beyond the established indication.

Key Studies & References

  1. Diclofenac Gel Cleared Actinic Keratoses After Transplant (Study in Immunosuppressed Patients)
  2. A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis (Trial comparing formulations/bioequivalence)
  3. Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (Comparative Trial Protocol)

Frequently Asked Questions (FAQ)

Common questions about Sunactic (FAQ)


Q: If I miss a dose of Sunactic, what is the generally accepted advice?

Official patient counseling information suggests applying the missed dose as soon as remembered, unless it is nearly time for your next scheduled application. If it is close to the next dose, the regulatory document suggests skipping the missed application and continuing with the regular schedule. Official information states that a person should never use two doses at once to compensate for a missed dose.

Q: What happens if I stop taking Sunactic suddenly?

Studies on Sunactic's approved use for Actinic Keratosis indicate that the full therapeutic effect may not be apparent until up to 30 days after therapy is stopped. Regulatory documents state that use should be immediately discontinued if a user experiences signs of a serious skin reaction or has concerns about liver function. Discontinuation of treatment is a decision that is best discussed with a healthcare professional.

Q: Are there any known interactions between Sunactic and herbal supplements?

Official drug labels primarily focus on interactions with other prescription medications and alcohol. There is often limited or no data available regarding the specific effects of Sunactic when combined with complementary or herbal remedies. Guidance on using herbal or complementary remedies is generally obtained from a healthcare professional.

Q: What should I do if I feel worse after starting Sunactic?

Official patient counseling describes symptoms of serious problems and advises that the product be stopped immediately if a user experiences them, such as chest pain, difficulty breathing, unusual bleeding, or a severe skin rash. This guidance is included in the official labeling to address the risks associated with this class of medicine and systemic adverse events.

Q: Can Sunactic be crushed or split if a person has trouble swallowing pills?

Sunactic is only manufactured and supplied as a topical gel meant for application to the skin, not as a tablet or capsule that is swallowed. Therefore, instructions for crushing or splitting are not applicable to this product, as it is not an oral medication.

Q: Is Sunactic safe for people with liver disease, according to official guidelines?

Official labeling advises monitoring liver function in patients with existing liver problems (hepatic impairment) during use. Regulatory documents state that use may need to be discontinued if a patient develops clinical signs of liver disease or if liver test results persist or worsen.

Q: What happens if I accidentally take two doses of Sunactic?

If a person accidentally uses slightly more than the recommended amount of the gel on their skin, it is generally considered unlikely to cause a problem. However, if the gel is accidentally swallowed, or if a user applies a very large amount and then experiences systemic side effects, contacting a healthcare professional is recommended in such circumstances.

Q: Is Sunactic a maintenance medication, or is it used only when needed?

Official guidance states that this medicine should be used at the lowest effective amount for the shortest duration possible. It is generally not intended for long-term maintenance unless specifically directed for a chronic condition, and treatment is often reviewed after a short course.

Q: How quickly can I expect Sunactic to start working?

Sunactic is not intended to provide immediate relief. According to patient information, it may take up to seven days before a user notices relief of pain associated with the treated condition. If pain is unrelieved after seven days, official information suggests that the use of the product should be discontinued.

Q: Does Sunactic cause drowsiness or affect alertness?

Some systemic side effects, such as dizziness or headache, may be experienced due to the systemic absorption of the NSAID. Official labeling notes that caution is to be used when driving or operating machinery if side effects such as dizziness or lightheadedness are experienced.

Q: Can Sunactic be taken safely with common pain relievers like ibuprofen?

Official warnings state that the concomitant use of Sunactic with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen, or with aspirin, is not recommended. This is due to an increased risk of serious adverse effects.

Q: Is Sunactic addictive or habit-forming?

The active ingredient in Sunactic, diclofenac sodium, is not classified as a controlled substance by regulatory agencies. It has no known association with being addictive or habit-forming.

Q: Why do some people experience stomach upset with Sunactic?

Sunactic belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, which carries a documented risk of serious stomach and intestinal problems, including bleeding. This risk is related to a small amount of the active ingredient being absorbed into the body (systemic absorption), even when applied topically.

Q: Does taking Sunactic mean I am cured of my condition?

The official mechanism of action is described as managing symptoms of pain and inflammation by inhibiting biological signals. Sunactic is intended for the relief of pain associated with a condition, but its action is symptomatic and does not influence the underlying pathological mechanisms of the disease.

Q: Is Sunactic considered a controlled substance?

No, Sunactic’s active ingredient, diclofenac sodium, is not listed as a controlled substance by the US Drug Enforcement Administration (DEA) or other major international regulatory bodies.

Q: Is there a specific time of day Sunactic is usually recommended to be taken?

The official dosing is specified as four times daily (QID) for the approved indication. While this suggests applications should be spaced out to maintain a consistent level in the body, regulatory documents do not specify a particular time of day (such as morning, noon, or night) for application.

Q: What is the official information regarding Sunactic and breastfeeding?

Reviewers of drug information regarding breastfeeding note that diclofenac is generally considered compatible with use by a nursing parent. Because the topical form results in low systemic absorption, the risk of adverse effects for the breastfed infant is considered to be low.

Q: Can I buy Sunactic over the counter?

Some formulations of diclofenac sodium topical gel have received approval from regulatory authorities for a transition from prescription-only status to over-the-counter (OTC) status. This means certain products containing the active ingredient may be available for purchase without a prescription.

Q: Are there different brand names or generics available for the active ingredient in Sunactic?

Yes, the active ingredient in Sunactic, diclofenac sodium, is found in many different topical gel products. It is widely available under various brand names and in generic formulations at similar concentrations.

Q: Can Sunactic make my skin more sensitive to the sun?

Yes, official labeling includes a warning about the risk of photosensitivity (increased sensitivity to light). Official warnings include advice that the treated skin areas should be protected from exposure to natural and artificial sunlight, including tanning beds, during treatment and for a period following treatment.

How should Sunactic be stored and disposed of?

Storage and Environmental Control

Sunactic (Diclofenac Sodium Topical Gel) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The official labeling mandates that the gel must be kept from freezing and stored away from excess heat. The container should be kept tightly closed in the original tube to protect the product from light and moisture.

Stability and Child Safety

For stability, some regulatory documents specify that the gel must be used within 28 days (or 6 months, depending on formulation) after first opening the tube. Like all medicines, the gel must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal and Handling Requirements

The product must not be discarded into wastewater (drains or toilets) due to the risk it poses to the aquatic environment. Unused or expired gel should be disposed of in accordance with local requirements, often by consulting a healthcare professional or using a drug take-back program. A labeled handling warning notes the serious fire hazard posed by fabrics that have been in contact with the gel; do not smoke or go near naked flames.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sunactic found in:

A-Z Index: